山東金(jin)城(cheng)(cheng)醫(yi)(yi)藥(yao)集團股份(fen)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(簡稱(cheng)“金(jin)城(cheng)(cheng)醫(yi)(yi)藥(yao)”,股票代碼:300233)成(cheng)(cheng)立于2004年(nian),創業(ye)(ye)(ye)板(ban)上市企(qi)業(ye)(ye)(ye)。目前,公(gong)(gong)司(si)擁有(you)(you)北京朗依(yi)制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、上海(hai)金(jin)城(cheng)(cheng)藥(yao)業(ye)(ye)(ye)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、廣東金(jin)城(cheng)(cheng)金(jin)素制藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、山東金(jin)城(cheng)(cheng)生(sheng)(sheng)物(wu)藥(yao)業(ye)(ye)(ye)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、山東金(jin)城(cheng)(cheng)醫(yi)(yi)藥(yao)化工有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、山東金(jin)城(cheng)(cheng)石墨烯科技有(you)(you)限(xian)(xian)公(gong)(gong)司(si)、意大利海(hai)寶(bao)露有(you)(you)限(xian)(xian)責任(ren)公(gong)(gong)司(si)等18家參控(kong)股公(gong)(gong)司(si)。公(gong)(gong)司(si)通過(guo)“實業(ye)(ye)(ye)+資本(ben)”雙(shuang)輪驅(qu)動發展模式,已構建形(xing)成(cheng)(cheng)獨具金(jin)城(cheng)(cheng)特色的醫(yi)(yi)藥(yao)健康制藥(yao)工業(ye)(ye)(ye)產業(ye)(ye)(ye)鏈(lian),業(ye)(ye)(ye)務范圍涉(she)及生(sheng)(sheng)物(wu)制藥(yao)、頭孢類醫(yi)(yi)藥(yao)中間體、特色原料(liao)藥(yao)、終(zhong)端制劑、保(bao)健品、新材料(liao)等產業(ye)(ye)(ye)領域,并現已形(xing)成(cheng)(cheng)年(nian)營(ying)業(ye)(ye)(ye)收(shou)入超(chao)20億(yi)元(yuan)、總資產近50億(yi)的產業(ye)(ye)(ye)規模。
山東金(jin)城醫(yi)藥(yao)集團(tuan)股份(fen)有(you)限(xian)公司是(shi)以(yi)三、四代頭(tou)孢類醫(yi)藥(yao)中(zhong)間(jian)體(ti)、特(te)色(se)原料(liao)藥(yao)、生(sheng)物制(zhi)藥(yao)、終端(duan)制(zhi)劑以(yi)及婦兒產(chan)品等(deng)為主(zhu)業(ye)的科(ke)研(yan)、生(sheng)產(chan)企業(ye),其中(zhong),頭(tou)孢類醫(yi)藥(yao)中(zhong)間(jian)體(ti)產(chan)品銷(xiao)量、銷(xiao)售收入連(lian)續多年位居行業(ye)前(qian)列,是(shi)重要的生(sheng)物制(zhi)藥(yao)生(sheng)產(chan)基地以(yi)及國(guo)內醫(yi)藥(yao)健康產(chan)業(ye)集團(tuan)。主(zhu)導產(chan)品有(you)谷胱甘肽(tai)(花(hua)青(qing)肽(tai)美品牌(pai))、硝呋(fu)太爾膠囊(朗依品牌(pai))、富馬酸比(bi)索洛(luo)爾膠囊(洛(luo)雅品牌(pai))、牡蠣碳酸鈣咀嚼片(金(jin)娃寧品牌(pai))、復方木香鋁鎂片(德瑞夫品牌(pai))等(deng)近(jin)百種(zhong)。
當(dang)前,公(gong)司堅持科學(xue)發(fa)展(zhan),按照“大(da)健(jian)(jian)康(kang)、大(da)醫藥,打(da)(da)造具有(you)金城(cheng)特色(se)制(zhi)藥產(chan)(chan)業(ye)(ye)(ye)鏈”的(de)(de)產(chan)(chan)業(ye)(ye)(ye)定位(wei)和“調整、轉型(xing)、升級、發(fa)展(zhan)”的(de)(de)戰略(lve)思路,專(zhuan)注專(zhuan)注金城(cheng)特色(se)制(zhi)藥產(chan)(chan)業(ye)(ye)(ye)鏈三(san)大(da)方向建設(she)——“頭孢類抗生(sheng)素終端制(zhi)劑產(chan)(chan)業(ye)(ye)(ye)鏈,多肽類特色(se)生(sheng)物(wu)制(zhi)藥產(chan)(chan)業(ye)(ye)(ye)鏈和婦科、調節免疫制(zhi)劑特色(se)類產(chan)(chan)業(ye)(ye)(ye)鏈 ”。同時,公(gong)司加(jia)快“三(san)個平臺”建設(she)(技術創新平臺、產(chan)(chan)業(ye)(ye)(ye)運營平臺、組織管控平臺),加(jia)快打(da)(da)造“四支隊伍(wu)(wu)”建設(she)(企業(ye)(ye)(ye)家隊伍(wu)(wu)、中高層(ceng)管理隊伍(wu)(wu)、專(zhuan)業(ye)(ye)(ye)人(ren)才(cai)隊伍(wu)(wu)、熟練工(gong)人(ren)隊伍(wu)(wu)),積極實踐內涵式發(fa)展(zhan)、外延式擴(kuo)張和投資(zi)并購三(san)種發(fa)展(zhan)方式,著力(li)將公(gong)司打(da)(da)造成(cheng)“科技化(hua)、生(sheng)態化(hua)、規范化(hua)、品牌化(hua)、國際化(hua)”的(de)(de)現代(dai)化(hua)醫藥健(jian)(jian)康(kang)產(chan)(chan)業(ye)(ye)(ye)集團,助推醫藥進步,創享健(jian)(jian)康(kang)生(sheng)活,志在成(cheng)為醫藥健(jian)(jian)康(kang)產(chan)(chan)業(ye)(ye)(ye)創新型(xing)領軍企業(ye)(ye)(ye)。